Categories: News

Noranda Income Fund Achieves 2020 Zinc Production Guidance

TORONTO, Jan. 08, 2021 (GLOBE NEWSWIRE) — Noranda Income Fund (TSX:NIF.UN) (the “Fund”) today announced that its electrolytic zinc processing facility (the “Processing Facility”) located in Salaberry-de-Valleyfield, Québec, has met its 2020 zinc metal production guidance of between 260,000 and 270,000 tonnes. Zinc metal production increased 2.1% to 268,387 tonnes from 262,965 tonnes in 2019.

2020 Fourth Quarter and Full Year Results
The Fund expects to report its full financial and operational results for the fourth quarter and full year ended December 31, 2020 at the end of February 2021.

Noranda Income Fund is an income trust whose units trade on the Toronto Stock Exchange under the symbol “NIF.UN”. Noranda Income Fund owns the electrolytic zinc processing facility and ancillary assets (the “Processing Facility”) located in Salaberry-de-Valleyfield, Québec. The Processing Facility is the second-largest zinc processing facility in North America and the largest zinc processing facility in eastern North America, where the majority of zinc customers are located. It produces refined zinc metal and various by-products from sourced zinc concentrates. The Processing Facility is operated and managed by Canadian Electrolytic Zinc Limited, a wholly-owned subsidiary of Glencore Canada Corporation. Further information about Noranda Income Fund can be found at: www.norandaincomefund.com.

For further information, please contact:
Noranda Income Fund:
Paul Einarson
Chief Financial Officer of Canadian Electrolytic Zinc Limited, Noranda Income Fund’s Manager
Tel: 514-745-9380
info@norandaincomefund.com

Staff

Recent Posts

World Orphan Drug Alliance expands to Canada and full LATAM region, completing the first truly global commercialization offering

By adding Canada and the entire Latin America region, including Mexico, WODA completes its full…

1 second ago

Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change

COPENHAGEN, Denmark, January 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio…

7 seconds ago

ORYZON to Provide Corporate Progress Updates at Several Events in January-February

8th Sachs Annual Neuroscience Innovation Forum14th Annual LifeSci Advisors Corporate Access EventInvest Securities BioMed Forum…

14 seconds ago

scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

Preliminary unaudited fourth quarter 2024 net revenue expected to be approximately $12 million to $12.3…

22 seconds ago

Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update

Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025Postponing further clinical development…

29 seconds ago

4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path

Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no…

33 seconds ago